Psilocybin in magic mushrooms shows a relief of the 5 -year depression after a single dose, the results of the study

Psilocybin, the main psychoactive ingredient of magic fungi, could alleviate depression for at least five years after a single dose, according to a new study.

Research, presented on June 18 at the Psychedelic Science 2025 conference in Denver, followed with patients who had been diagnosed with clinical depression – also known as a major depressive disorder (MDD) – and participated in a previous study of psilocybine treatment in 2020.

“Most of the people who participated in our trial reported improvements in the intensity of depression symptoms or the way they have experienced depression in their lives, lasting up to five years after the trial,” said the study co-author, Alan Davis, director of the Center for Psychedelic Drug Research and Education at Ohio State University.

Psychedelics as potential mental health treatment are explored by the Trump administration

Doug Drysdale, CEO of the Canadian Pharmaceutical Company Cybin in Toronto, Ontario, told Fox News Digital that the result testified to the “exciting” potential of psilocybin and other treatments based on psychedelic in the treatment of DRAD and other mental health problems.

“The results of the study are certainly very encouraging,” said Drysdale, who was not involved in the study.

A worker holds dried psychedelic mushrooms. The results of the new study are “certainly very encouraging,” said a framework for the pharmaceutical company. (James Macdonald / Bloomberg via Getty Images)

Previous studies have underlined the possibility of psilocybin as a potential antidepressant, which prompted researchers to conduct the very first randomized clinical trial.

The initial trial of 2020, published in Jama Psychiatry, included 24 patients with major depressive disorder. Half received psilocybin at the start of the test, and the other half received the treatment eight weeks later.

Each patient also suffered 11 hours of psychotherapy.

What is ketamine therapy? Stars of Mormone reality praise controversial treatment

One month after treatment, 17 patients said they had been relieved of symptoms. Fourteen of those reported a complete remission of depression, according to the published study.

“The efficiency of psilocybine therapy after a single or only a few administrations represents another substantial advantage compared to commonly used antidepressants which require daily administration,” the researchers wrote.

Patients seemed to respond much faster to psychedelics than traditional antidepressants, researchers said. (James Macdonald / Bloomberg via Getty Images)

The new study aimed to explore the longer -term effects of this treatment out of 21 of the participants in the original trial.

Sixty-seven percent declared that they are in remission of depression five years after treatment, and they also had less anxiety and easier daily operation.

“The study does not take into account naturalistic changes which could have affected their depression in the five years which followed the main trial.”

For those whose depression has returned, many have further reported lasting advantages in their attitudes, their prospects and their ability to pursue things that were significant for them, Davis in Fox News Digital told.

“Admittedly, a more controlled and rigorous study is necessary, but at least anecdotal, these results are very interesting, and I am carefully optimistic about the prolonged efficiency potential provided by these types of treatments,” added Drysdale.

Sixty-seven percent of the participants said they were in remission of depression five years after treatment, and they also had less anxiety and easier daily operation. (Jason Connolly / AFP via Getty Images)

Other factors may also have played a role in the long -term advantages of the mental health of participants, such as psychotherapy sessions or other antidepressants, have accepted experts.

“The study does not take into account naturalistic changes that could have assigned their depression in the five years that followed the main trial, and the sample is not representative of the population of people with depression,” Davis in Fox News Digital told Fox.

Parkinson patients who take “magic fungi” see key advantages, study results

Psilocybin has also been explored as a potential treatment for postpartum depression (PPD), which affects up to a new mother in seven.

A study in 2022 described the potential role of psychedelics in cases of PPD, noting that psilocybin has been demonstrated to catalyze a feeling of “reconnection” among new mothers.

Click here to register for our Health Newsletter

“This effect in PPD, by promoting a feeling of” reconnection “for the mother, can allow an improvement in mood and maternal sensitivity to infants, which can have a positive impact on the gratuity of maternal roles and the mother-child relationship,” said researchers.

In February, Cleveland Clinic reported an upcoming study that explores unique psilocybin as a means of treating PPD.

Psilocybin was explored as a potential treatment of postpartum depression (PPD), which affects up to a new mother in seven. (istock)

The test, now in its second phase, focuses on RE104, an owner medication similar to psilocybine.

Study participants will undergo several physical and mental health tests.

Potential risks and limitations

Ryan Moss, Director of Sciences of Filament Health, a society for the development of natural psychedelic drugs at the clinical stage in Canada, stressed the importance of administering psychedelics in a safe setting during the treatment of mental health problems.

For more health items, visit www.foxnews.com/health

“Psychedelic experiences can sometimes offer anxiety, hallucinations and paranoia,” said Moss to Fox News Digital.

Experts recommend that the therapeutic use of psychedelics is carefully managed by medical experts.

“Some patients using traditional psychedelics have reported unwanted cardiovascular events during clinical trials.”

To mitigate these risks, participants in Moss recommended clinical trials receive in -depth preparation and monitoring by professionals trained during the sessions.

Other factors may also have played a role in the long -term mental health benefits of participants, noted an expert (not illustrated), such as psychotherapy sessions or other antidepressants. (istock)

Dr. Marc Siegel, professor of medicine in clinic at Nyu Langone Medical Center And Fox News’ principal medical analyst, previously interviewed two of the best researchers in the country on psychedelics: Dr. Rachel Yehuda, founder and director of the Center for PsycheDelic Psychotherapy and Trauma Research at MT. Sinai in New York, and Dr. Charles Marmar, director of the PTSD research program in Nyu Langone.

Click here to obtain the Fox News app

“They agree that there is a therapeutic potential if it is very carefully studied under very strict medical advice, but there is a huge drawback in terms of unregulated recreational uses,” Siegel told Fox News Digital at the time.

“The two doctors see a probable therapeutic value for psychedelics if they are carefully managed by medical experts“Added Siegel.

Melissa Rudy and Angelica Stabile, both of Fox News Digital, contributed reports.